News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017

Biotronik Launches DX Technology for U.S. Heart Failure Patients

Intica DX device systems provide complete atrial diagnostics with less hardware to reduce complications

Biotronik Launches DX Technology for U.S. Heart Failure Patients

July 21, 2017 — Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica cardiac resynchronization therapy (CRT)-DX implantable cardioverter defibrillator (ICD) systems. The launch of Intica CRT-DX extends the benefits of Biotronik's DX technology to heart failure patients. DX eliminates the need for an atrial lead while still providing physicians with critical diagnostic information based on a true atrial signal.

Biotronik launched DX technology in 2013 with a focus on improving patient care and decreasing the rate of complication. DX minimizes hardware and provides critical diagnostics that allow physicians to better monitor, manage and prevent cardiac events. Intica CRT-DX is the first cardiac rhythm management device for the treatment of heart failure patients that delivers atrial diagnostics without an atrial lead. Atrial diagnostics aid physicians in the early identification of supraventricular tachycardia (SVT), atrial fibrillation (AF) and atrial ventricular synchronization.

"When treating heart failure patients, we are often managing several comorbidities that can increase the likelihood of complications and risk when implanting a CRT-D and in the years that follow," said Larry Chinitz, M.D., a cardiac electrophysiologist in New York City. "Balancing risk and therapeutic needs has historically been a challenge. CRT-DX changes this and creates a higher echelon of patient care. Now there is an ICD for heart failure patients that minimizes hardware and risk while providing optimal diagnostics to help patients feel better and stay out of the hospital. The addition of DX technology to a CRT device is a breakthrough."

Intica CRT-DX also includes Biotronik's recently FDA approved MultiPole Pacing (MPP) technology. MPP enables the left ventricle (LV) to be paced twice per cardiac cycle — sequentially or simultaneously — allowing for even greater customization of heart failure therapy.

Only Biotronik offers MR conditional devices with independent, simultaneous LV paces, according to the company.

The Intica DX device systems also incorporate other technologies including:

  • MRI AutoDetect – shortens window of reduced therapy and eliminates the need for post-MRI (magnetic resonance imaging) reprogramming;
  • Biotronik Home Monitoring – automatically transmits device data daily; associated with a >50 percent reduction in mortality due to heart failure and a 36 percent reduction in hospitalization for worsening heart failure; and
  • Closed Loop Stimulation – equips the device to respond appropriately to physiologic demands and acute mental stress.

For more information: www.biotronik.com

Related Content

Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT) | April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
Overlay Init